The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted ...
providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole ...
Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall ...
Venatorx suffered a setback in February when its new drug application for a urinary tract infection treatment was rejected by ...
The FDA recently approved Pivya for uncomplicated UTIs. Pivya is an oral tablet that clears bacterial infections in the ...
as well as a treatment for complicated UTI. NRXP has achieved a series of important milestones over the past several months in the company’s progression towards the final approval and commercial ...
But it’s likely to be years before MV140 is approved for wider use ... which provides UTI-treatment guidelines to clinicians across Europe, to strongly recommend the use of methenamine ...
By Nicholas Van Sickles University of Kentucky A safe and effective medication designed to prevent mild-to-moderate COVID-19 ...
Recently, MV140 was approved in Mexico and the ... The median time to the first urinary tract infection after 3 months of treatment was 275.0 days in the MV140 groups compared with 48.0 days ...
A study in eClinicalMedicine explores the relationship between gut microbiota, urinary tract colonization ... other urological disorders, with treatment options including urotherapy, biofeedback ...
The Food and Drug Administration (FDA) has approved Pivya (pivmecillinam) for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (UTIs) caused by ...